<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1409222607
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Rigorixa
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CELECOXIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        25.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ALPHA PHARMA INDUSTRY " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2732]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Alpha Pharma Industry
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ALPHA PHARMA INDUSTRY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Rigorixa</strong> is used in adults for the relief of signs and symptoms of <strong>rheumatoid arthritis, osteoarthritis</strong> and <strong>ankylosing spondylitis</strong>.</p><p>&nbsp;<strong>Rigorixa</strong> belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAID), and specifically a sub-group known as cyclooxygenase-2 (COX-2) inhibitors. Your body makes prostaglandins that may cause pain and inflammation. In conditions such as rheumatoid arthritis and osteoarthritis your body makes more of these. <strong>Rigorixa</strong> acts by reducing the production of prostaglandins, thereby reducing the pain and inflammation.</p><p>You should expect your medicine to start working within hours of taking the first dose, but you may not experience a full effect for several days.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You have been prescribed <strong>Rigorixa</strong> by your doctor. The following information will help you get the best results with <strong>Rigorixa</strong>. If you have any further questions please ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Do not take Rigorixa</strong></p><p>Tell your doctor if any of the following are true for you as patients with these conditions should not take <strong>Rigorixa</strong>.</p><p>&bull; If you are allergic to celecoxib or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull; If you have had an allergic reaction to a group of medicines called &ldquo;sulfonamides&rdquo; (e.g. some antibiotics used to treat infections)</p><p>&bull; If you currently have an ulcer in your stomach or intestines, or bleeding in your stomach or intestines</p><p>&bull; If as a result of taking acetylsalicylic acid or any other anti-inflammatory and pain-relieving medicine (NSAID) you have had asthma, nose polyps, severe nose congestion, or an allergic reaction such as an itchy skin rash, swelling of the face, lips, tongue or throat, breathing difficulties or wheezing</p><p>&bull; If you are pregnant. If you can become pregnant during ongoing treatment you should discuss methods of contraception with your doctor</p><p>&bull; If you are breast-feeding</p><p>&bull; If you have severe liver disease</p><p>&bull; If you have severe kidney disease</p><p>&bull; If you have an inflammatory disease of the intestines such as ulcerative colitis or Crohn&rsquo;s disease</p><p>&bull; If you have heart failure, established ischaemic heart disease, or cerebrovascular disease, e.g. you have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary reduction of blood flow to the brain; also known as &ldquo;mini-stroke&rdquo;), angina, or blockages of blood vessels to the heart or brain</p><p>&bull; If you have or have had problems with your blood circulation (peripheral arterial disease) or if you have had surgery on the arteries of your legs</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking <strong>Rigorixa</strong>:</p><p>&bull; If you have previously had an ulcer or bleeding in your stomach or intestines. (Do not take <strong>Rigorixa</strong> if you currently have an ulcer or bleeding in your stomach or intestine)</p><p>&bull; If you are taking acetylsalicylic acid (even at low dose for heart protective purposes)</p><p>&bull; If you are taking antiplatelet therapies</p><p>&bull; If you use medicines to reduce blood clotting (e.g. warfarin/warfarin like anticoagulants or novel oral anti-clotting medicines, e.g. apixaban)</p><p>&bull; If you use medicines called corticosteroids (e.g. prednisone)</p><p>&bull; If you are using <strong>Rigorixa</strong> at the same time as other non-acetylsalicylic NSAIDs such as ibuprofen or diclofenac. The use of these medicines together should be avoided</p><p>&bull; If you smoke, have diabetes, raised blood pressure or raised cholesterol</p><p>&bull; If your heart, liver or kidneys are not working well your doctor may want to keep a regular check on you</p><p>&bull; If you have fluid retention (such as swollen ankles and feet)</p><p>&bull; If you are dehydrated, for instance due to sickness, diarrhoea or the use of diuretics (used to treat excess fluid in the body)</p><p>&bull; If you have had a serious allergic reaction or a serious skin reaction to any medicines</p><p>&bull; If you feel ill due to an infection or think you have an infection, as <strong>Rigorixa</strong> may mask a fever or other signs of infection and inflammation</p><p>&bull; If you are over 65 years of age your doctor will want to monitor you regularly</p><p>&bull; The consumption of alcohol and NSAIDs may increase the risk of gastrointestinal problems</p><p>&nbsp;</p><p>As with other NSAIDs (e.g. ibuprofen or diclofenac) this medicine may lead to an increase in blood pressure, and so your doctor may ask to monitor your blood pressure on a regular basis. Some cases of severe liver reactions, including severe liver inflammation, liver damage, liver failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. <u>Of the cases that reported time to onset, most severe liver reactions occurred within one month of start of treatment.</u></p><p><strong>Rigorixa</strong> may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems to become pregnant (see section on Pregnancy and breast-feeding).</p><p><strong>Other medicines and Rigorixa</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines:</p><p>&bull; Dextromethorphan (used to treat coughs)</p><p>&bull; ACE inhibitors, angiotensin II antagonists, beta blockers and diuretics (used for high blood pressure and heart failure)</p><p>&bull; Fluconazole and rifampicin (used to treat fungal and bacterial infections)</p><p>&bull; Warfarin or other warfarin like medicines (&ldquo;blood-thinning&rdquo; agents that reduce blood clotting) including newer medicines like apixaban</p><p>&bull; Lithium (used to treat some types of depression)</p><p>&bull; Other medicines to treat depression, sleep disorders, high blood pressure or an irregular heartbeat</p><p>&bull; Neuroleptics (used to treat some mental disorders)</p><p>&bull; Methotrexate (used to treat rheumatoid arthritis, psoriasis and leukaemia)</p><p>&bull; Carbamazepine (used to treat epilepsy/seizures and some forms of pain or depression)</p><p>&bull; Barbiturates (used to treat epilepsy/seizures and some sleep disorders)</p><p>&bull; Ciclosporin and tacrolimus (used for immune system suppression e.g. after transplants)</p><p>&nbsp;</p><p><strong>Rigorixa</strong> can be taken with low dose acetylsalicylic acid (75 mg or less daily). Ask your doctor for advice before taking both medicines together.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><u>Pregnancy</u></p><p><strong>Rigorixa</strong> must not be used by women who are pregnant or can become pregnant (i.e. women of child bearing potential who are not using adequate contraception) during ongoing treatment. If you become pregnant during treatment with <strong>Rigorixa</strong> you should discontinue the treatment and contact your doctor for alternative treatment.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p><strong>Rigorixa</strong> must not be used during breast-feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>NSAIDs, including <strong>Rigorixa</strong>, may make it more difficult to become pregnant. You should tell your doctor if you are planning to become pregnant or if you have problems becoming pregnant.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You should be aware of how you react to <strong>Rigorixa</strong> before you drive or operate machinery. If you feel dizzy or drowsy after taking <strong>Rigorixa</strong>, do not drive or operate machinery until these effects wear off.</p><p><strong>Rigorixa contains lactose</strong></p><p><strong>Rigorixa</strong> contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. If you think or feel that the effect of <strong>Rigorixa</strong> is too strong or too weak, talk to your doctor or pharmacist.</p><p>Your doctor will tell you what dose you should take. As the risk of side effects associated with heart problems may increase with dose and duration of use, it is important that you use the lowest dose that controls your pain and you should not take <strong>Rigorixa</strong> for longer than necessary to control symptoms.</p><p><u>Method of administration:</u></p><p><strong>Rigorixa</strong> is for oral use. The capsules can be taken at any time of the day, with or without food. However, try to take each dose of <strong>Rigorixa</strong> at the same time each day</p><p>Contact your doctor within two weeks of starting treatment if you do not experience any benefit.</p><p><u>The recommended dose is:</u></p><p><strong>For osteoarthritis</strong> the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.</p><p>The dose is usually:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 200 mg capsule once a day</p><p>&nbsp;</p><p><strong>For rheumatoid arthritis</strong> the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.</p><p>The dose is usually:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 200 mg capsule once a day.</p><p>&nbsp;</p><p><strong>For ankylosing spondylitis</strong> the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.</p><p>The dose is usually:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 200 mg capsule once a day</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Kidney or liver problems:</strong> make sure your doctor knows if you have liver or kidney problems as you may need a lower dose.</p><p><strong>The elderly, especially those with a weight less than 50 kg:</strong> if you are over 65 years of age and especially if you weigh less than 50 kg, your doctor may want to monitor you more closely.</p><p>You should not take more than 400 mg per day.</p><p><strong>Use in children</strong></p><p><strong>Rigorixa</strong> is for adults only, it is not for use in children.</p><p><strong>If you take more Rigorixa than you should</strong></p><p>You should not take more capsules than your doctor tells you to. If you take too many capsules contact your doctor, pharmacist or hospital and take your medicine with you.</p><p>&nbsp;</p><p><strong>If you forget to take Rigorixa</strong></p><p>If you forget to take a capsule, take it as soon as you remember. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop taking Rigorixa</strong></p><p>Suddenly stopping your treatment with <strong>Rigorixa</strong> may lead to your symptoms getting worse. Do not stop taking <strong>Rigorixa</strong> unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>The side effects listed below were observed in arthritis patients who took Rigorixa. Side effects marked with an asterisk (*) are listed below at the higher frequencies that occurred in patients who took Rigorixa to prevent colon polyps. Patients in these studies took Rigorixa at high doses and for a long duration.</strong></p><p><strong>If any of the following happen, stop taking Rigorixa and tell your doctor immediately:</strong></p><p><strong>If you have:</strong></p><p>- An allergic reaction such as skin rash, swelling of the face, wheezing or difficulty breathing</p><p>- Heart problems such as pain in the chest</p><p>- Severe stomach pain or any sign of bleeding in the stomach or intestines, such as passing black or bloodstained stools, or vomiting blood</p><p>- A skin reaction such as rash, blistering or peeling of the skin</p><p>- Liver failure (symptoms may include nausea (feeling sick), diarrhoea, jaundice (your skin or the whites of your eyes look yellow)).</p><p>&nbsp;</p><p><strong>Very common: may be affect more than 1 in 10 people</strong></p><p>&bull; High blood pressure, including worsening of existing high blood pressure *</p><p><strong>Common: may be affect up to 1 in 10 people</strong></p><p>&bull; Heart attack*</p><p>&bull; Fluid build-up with swollen ankles, legs and/or hands</p><p>&bull; Urinary infections</p><p>&bull; Shortness of breath*, sinusitis (sinus inflammation, sinus infection, blocked or painful sinuses), blocked or runny nose, sore throat, coughs, colds, flu-like symptoms</p><p>&bull; Dizziness, difficulty sleeping</p><p>&bull; Vomiting*, stomach ache, diarrhoea, indigestion, wind</p><p>&bull; Rash, itching</p><p>&bull; Muscle stiffness</p><p>&bull; Difficulty swallowing*</p><p>&bull; Headache</p><p>&bull; Nausea (feeling sick)</p><p>&bull; Painful joints</p><p>&bull; Worsening of existing allergies</p><p>&bull; Accidental injury</p><p>&nbsp;</p><p><strong>Uncommon: may be affect up to 1 in 100 people</strong></p><p>&bull; Stroke*</p><p>&bull; Heart failure, palpitations (awareness of heart beat), fast heart rate</p><p>&bull; Abnormalities in liver-related blood tests</p><p>&bull; Abnormalities in kidney-related blood tests</p><p>&bull; Anaemia (changes in red blood cells that can cause fatigue and breathlessness)</p><p>&bull; Anxiety, depression, tiredness, drowsiness, tingling sensations (pins and needles)</p><p>&bull; High levels of potassium in blood test results (can cause nausea (feeling sick), fatigue, muscle weakness or palpitations)</p><p>&bull; Impaired or blurred vision, ringing in the ears, mouth pain and sores, difficulty hearing*</p><p>&bull; Constipation, burping, stomach inflammation (indigestion, stomach ache or vomiting), worsening of inflammation of the stomach or intestine</p><p>&bull; Leg cramps</p><p>&bull; Raised itchy rash (hives)</p><p>&bull; Eye inflammation</p><p>&bull; Difficulty breathing</p><p>&bull; Skin discolouration (bruising)</p><p>&bull; Chest pain (generalised pain not related to the heart)</p><p>&bull; Face swelling</p><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people</strong></p><p>&bull; Ulcers (bleeding) in the stomach, gullet or intestines; or rupture of the intestine (can cause stomach ache, fever, nausea, vomiting, intestinal blockage), dark or black stools, inflammation of the pancreas (can lead to stomach pain), inflammation of the gullet (oesophagus)</p><p>&bull; Low levels of sodium in the blood (a condition known as hyponatraemia)</p><p>&bull; Reduced number of white blood cells (which help to protect the body from infection) or blood platelets (increased chance of bleeding or bruising)</p><p>&bull; Difficulty coordinating muscular movements</p><p>&bull; Feeling confused, changes in the way things taste</p><p>&bull; Increased sensitivity to light</p><p>&bull; Loss of hair</p><p>&bull; Hallucinations</p><p>&bull; Bleeding in the eye</p><p>&bull; Acute reaction that may lead to lung inflammation</p><p>&bull; Irregular heartbeat</p><p>&bull; Flushing</p><p>&bull; Blood clot in the blood vessels in the lungs. Symptoms may include sudden breathlessness, sharp pains when you breathe or collapse</p><p>&bull; Bleeding of the stomach or intestines (can lead to bloody stools or vomiting), inflammation of the intestine or colon</p><p>&bull; Severe liver inflammation (hepatitis). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills</p><p>&bull; Acute kidney failure</p><p>&bull; Menstrual disturbances</p><p>&bull; Swelling of the face, lips, mouth, tongue or throat, or difficulty swallowing Very rare: may affect up</p><p>&nbsp; &nbsp;to 1 in 10,000 people</p><p>&bull; Serious allergic reactions (including potentially fatal anaphylactic shock)</p><p>&bull; Serious skin conditions such as Stevens-Johnson syndrome, exfoliative dermatitis and toxic epidermal necrolysis (can cause rash, blistering or peeling of the skin) and acute generalised exanthematous pustulosis (symptoms include the skin becoming red with swollen areas covered in numerous small pustules)</p><p>&bull; A delayed allergic reaction with possible symptoms such as rash, swelling of the face, fever, swollen glands, and abnormal test results (e.g., liver, blood cell (eosinophilia, a type of raised white blood cell count))</p><p>&bull; Bleeding within the brain causing death</p><p>&bull; Meningitis (inflammation of the membrane around the brain and spinal cord)</p><p>&bull; Liver failure, liver damage and severe liver inflammation (fulminant hepatitis) (sometimes fatal or requiring liver transplant). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills</p><p>&bull; Liver problems (such as cholestasis and cholestatic hepatitis, which may be accompanied by symptoms such as discoloured stools, nausea and yellowing of the skin or eyes)</p><p>&bull; Inflammation of the kidneys and other kidney problems (such as nephrotic syndrome and minimal change disease, which may be accompanied by symptoms such as water retention (oedema), foamy urine, fatigue and a loss of appetite)</p><p>&bull; Worsening of epilepsy (possible more frequent and/or severe seizures)</p><p>&bull; Blockage of an artery or vein in the eye leading to partial or complete loss of vision</p><p>&bull; Inflamed blood vessels (can cause fever, aches, and purple blotches on the skin)</p><p>&bull; A reduction in the number of red and white blood cells and platelets (may cause tiredness, easy bruising, frequent nose bleeds and increased risk of infections)</p><p>&bull; Muscle pain and weakness</p><p>&bull; Impaired sense of smell</p><p>&bull; Loss of taste</p><p>&nbsp;</p><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><p>&bull; Decreased fertility in females, which is usually reversible on discontinuation of the medicine</p><p><strong>In clinical studies not associated with arthritis or other arthritic conditions, where Rigorixa was taken at doses of 400 mg per day for up to 3 years, the following additional side effects have been observed:</strong></p><p><strong>Common: may affect up to 1 in 10 people</strong></p><p>&bull; Heart problems: angina (chest pain)</p><p>&bull; Stomach problems: irritable bowel syndrome (can include stomach ache, diarrhoea, indigestion, wind)</p><p>&bull; Kidney stones (which may lead to stomach or back pain, blood in urine), difficulty passing urine</p><p>&bull; Weight gain</p><p>&nbsp;</p><p><strong>Uncommon: may affect up to 1 in 100 people</strong></p><p>&bull; Deep vein thrombosis (blood clot usually in the leg, which may cause pain, swelling or redness of the calf or breathing problems)</p><p>&bull; Stomach problems: stomach infection (which can cause irritation and ulcers of the stomach and intestines)</p><p>&bull; Lower limb fracture</p><p>&bull; Shingles, skin infection, eczema (dry itchy rash), pneumonia (chest infection (possible cough, fever, difficulty breathing))</p><p>&bull; Floaters in the eye causing blurred or impaired vision, vertigo due to inner ear troubles, sore, inflamed or bleeding gums, mouth sores</p><p>&bull; Excessive urination at night, bleeding from piles/ haemorrhoids, frequent bowel movements</p><p>&bull; Fatty lumps in skin or elsewhere, ganglion cyst (harmless swellings on or around joints and tendons in the hand or foot), difficulty speaking, abnormal or very heavy bleeding from the vagina, breast pain</p><p>&bull; High levels of sodium in blood test results</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the blister and carton. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package. Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice any visible signs of deterioration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Celecoxib. Each 200 mg Capsule contains 200mg of Celecoxib.</p><p><strong>The other ingredients are:</strong></p><p>For the tablet core: Sodium Lauryl Sulfate, Povidone, Lactose Monohydrate, Croscarmellose Sodium, Sodium Stearyl Fumarate and filled in Hard Gelatine Capsule.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rigorixa 200mg Capsule: Opaque White with two gold band, imprint with JS14 in the cap,
and 200 in the body.
Rigorixa 200mg Capsules are available in blister packs containing 20 capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Alpha Pharma,</p><p>King Abdullah Economic city, Kingdom of Saudi Arabia</p><p>Tel:&nbsp;+966 12 21 29013</p><p>Email: regulatory@alphapharma.com.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                6/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يستخدم <strong>ريجوريكسا</strong> في البالغين للتخفيف من علامات وأعراض <strong>التهاب المفاصل</strong> <strong>الروماتويدي وهشاشة العظام والتهاب الفقار اللاصق</strong>.</p><p dir="RTL">&nbsp;ينتمي ريجوريكسا إلى مجموعة من الأدوية تسمى مضادات الالتهاب الغير الستيرويدية، وعلى وجه التحديد مجموعة فرعية تعرف باسم مثبطات انزيمات الأكسدة الحلقية 2. يصنع جسمك البروستاغلاندين التي قد تسبب الألم والالتهابات. في حالات مثل التهاب المفاصل الروماتويدي وهشاشة العظام، ينتج جسمك المزيد منها. يعمل ريجوريكسا عن طريق تقليل إنتاج البروستاجلاندين، وبالتالي تقليل الألم والالتهاب.</p><p dir="RTL">يبدأ الدواء الخاص بك في العمل في غضون ساعات من تناول الجرعة الأولى، ولكن ترى التأثير الكامل الا بعد انقضاء عدة أيام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">وصف لك طبيبك عقار <strong>ريجوريكسا</strong>. ستساعدك المعلومات التالية في الحصول على أفضل النتائج مع <strong>ريجوريكسا</strong>. إذا كانت لديك أسئلة أخرى ، فيرجى طرحها على طبيبك أو الصيدلي.</p><p dir="RTL"><strong>لا تأخذ ريجوريكسا</strong></p><p dir="RTL">أخبر طبيبك إذا كان أي مما يلي ينطبق عليك لأن المرضى الذين يعانون من هذه الحالات يجب ألا يأخذوا <strong>ريجوريكسا</strong>.</p><p dir="RTL">&bull; إذا كنت تعاني من حساسية تجاه السيليكوكسيب أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6)</p><p dir="RTL">&bull; إذا كان لديك رد فعل تحسسي تجاه مجموعة من الأدوية تسمى &quot;سلفوناميدات&quot; (على سبيل المثال ، بعض المضادات الحيوية المستخدمة لعلاج الالتهابات)</p><p dir="RTL">&bull; إذا كنت تعاني حاليًا من قرحة في معدتك أو أمعائك أو نزيف في معدتك أو أمعائك</p><p dir="RTL">&bull; إذا كنت تعاني من الربو أو الزوائد اللحمية بالأنف أو احتقان الأنف الشديد أو رد فعل تحسسي مثل طفح جلدي وحكة أو تورم في الوجه نتيجة تناول أسيتيل الساليسيليك (الأسبرين) أو أي دواء آخر مضاد للالتهاب ومسكن للألم، الشفتين، اللسان أو الحلق، صعوبات في التنفس أو صفير</p><p dir="RTL">&bull; إذا كنتِ حاملا. إذا كان بإمكانك الحمل أثناء العلاج المستمر، يجب عليك مناقشة طرق منع الحمل مع طبيبك</p><p dir="RTL">&bull; إذا كنتِ مرضعة</p><p dir="RTL">&bull; إذا كان لديك مرض كبدي حاد</p><p dir="RTL">&bull; إذا كنت تعاني من مرض شديد في الكلى</p><p dir="RTL">&bull; إذا كنت تعاني من مرض التهابي في الأمعاء مثل التهاب القولون التقرحي أو مرض كرون</p><p dir="RTL">&bull; إذا كنت تعاني من قصور في القلب، أو مرض قلبي إقفاري مؤكد، أو مرض دماغي وعائي، على سبيل المثال تم تشخيصك بنوبة قلبية أو سكتة دماغية أو نوبة إقفارية عابرة (انخفاض مؤقت في تدفق الدم إلى الدماغ ؛ يُعرف أيضًا باسم &quot;السكتة الدماغية الصغيرة&quot;) أو الذبحة الصدرية أو انسداد الأوعية الدموية للقلب أو الدماغ</p><p dir="RTL">&bull; إذا كنت تعاني أو عانيت من مشاكل في الدورة الدموية (مرض الشرايين المحيطية) أو إذا كنت قد خضعت لعملية جراحية في شرايين ساقيك</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول <strong>ريجوريكسا</strong>:</p><p dir="RTL">&bull; إذا سبق لك الإصابة بقرحة أو نزيف في معدتك أو أمعائك. (لا تأخذ <strong>ريجوريكسا</strong> إذا كنت تعاني حاليًا من قرحة أو نزيف في المعدة أو الأمعاء)</p><p dir="RTL">&bull; إذا كنت تتناول حمض أسيتيل الساليسيليك (الأسبرين) &nbsp;(حتى بجرعات منخفضة لأغراض حماية القلب)</p><p dir="RTL">&bull; إذا كنت تتناول علاجات مضادة للصفيحات</p><p dir="RTL">&bull; إذا كنت تستخدم أدوية لتقليل تخثر الدم (مثل الوارفارين / مضادات التخثر شبيهة الوارفارين أو الأدوية الجديدة المضادة للتخثر التي تؤخذ عن طريق الفم، مثل أبيكسابان)</p><p dir="RTL">&bull; إذا كنت تستخدم أدوية تسمى الكورتيكوستيرويدات (مثل بريدنيزون)</p><p dir="RTL">&bull; إذا كنت تستخدم <strong>ريجوريكسا</strong> في نفس الوقت مع مضادات الالتهاب غير الستيرويدية الأخرى غير الأسيتيل ساليسيليك مثل الإيبوبروفين أو الديكلوفيناك. يجب تجنب استخدام هذه الأدوية معًا</p><p dir="RTL">&bull; إذا كنت تدخن أو تعاني من مرض السكري أو ارتفاع ضغط الدم أو ارتفاع نسبة الكوليسترول</p><p dir="RTL">&bull; إذا كان قلبك أو كبدك أو كليتيك لا تعمل بشكل جيد ، فقد يرغب طبيبك في متابعة حالتك بانتظام</p><p dir="RTL">&bull; إذا كنت تعاني من احتباس السوائل (مثل تورم الكاحلين والقدمين)</p><p dir="RTL">&bull; إذا كنت تعاني من الجفاف ، على سبيل المثال بسبب المرض أو الإسهال أو استخدام مدرات البول (المستخدمة لعلاج السوائل الزائدة في الجسم)</p><p dir="RTL">&bull; إذا كان لديك رد فعل تحسسي خطير أو رد فعل جلدي خطير لأية أدوية</p><p dir="RTL">&bull; إذا شعرت بالمرض بسبب العدوى أو تعتقد أنك مصاب بعدوى ، فقد يخفي <strong>ريجوريكسا</strong> الحمى أو غيرها من علامات العدوى والالتهاب</p><p dir="RTL">&bull; إذا كان عمرك يزيد عن 65 سنة ، سيرغب طبيبك في مراقبتك بانتظام</p><p dir="RTL">&bull; قد يؤدي استهلاك الكحول ومضادات الالتهاب غير الستيرويدية إلى زيادة مخاطر حدوث مشاكل في الجهاز الهضمي</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال مع مضادات الالتهاب غير الستيرويدية الأخرى (مثل إيبوبروفين أو ديكلوفيناك)، قد يؤدي هذا الدواء إلى زيادة ضغط الدم ، وبالتالي قد يطلب طبيبك مراقبة ضغط الدم بشكل منتظم. تم الإبلاغ عن بعض حالات تفاعلات الكبد الحادة، بما في ذلك التهاب الكبد الحاد، وتلف الكبد، وفشل الكبد (بعضها مع نتائج مميتة أو تتطلب زراعة الكبد)، مع السيليكوكسيب.</p><p dir="RTL">&nbsp;<u>من بين الحالات التي تم الإبلاغ عن وقت ظهورها ، حدث معظم ردود الفعل الكبدية الشديدة في غضون شهر واحد من بدء العلاج.</u></p><p dir="RTL">قد يجعل <strong>ريجوريكسا</strong> من الصعب الحمل. يجب عليكِ إبلاغ طبيبك إذا كنتِ تخططين للحمل أو إذا كنتِ تعانين من مشاكل في الحمل (أنظري قسم الحمل والرضاعة).</p><p dir="RTL"><strong>الأدوية الأخرى و ريجوريكسا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى:</p><p dir="RTL">&bull; ديكستروميثورفان (يستخدم لعلاج السعال).</p><p dir="RTL">&bull; مثبطات الإنزيم المحول للأنجيوتنسين ومضادات الأنجيوتنسين 2 وحاصرات بيتا ومدرات البول (تستخدم لعلاج ارتفاع ضغط الدم و علاج فشل القلب)</p><p dir="RTL">&bull; فلوكونازول وريفامبيسين (يستخدمان لعلاج الالتهابات الفطرية والبكتيرية)</p><p dir="RTL">&bull; الوارفارين أو مثيلات الوارفارين الأخرى مثل الأدوية (عوامل &quot;ترقق الدم&quot; التي تقلل تخثر الدم) بما في ذلك الأدوية الأحدث مثل أبيكسابان</p><p dir="RTL">&bull; الليثيوم (يستخدم لعلاج بعض أنواع الاكتئاب).</p><p dir="RTL">&bull; أدوية أخرى لعلاج الاكتئاب واضطرابات النوم وارتفاع ضغط الدم أو عدم انتظام ضربات القلب</p><p dir="RTL">&bull; مضادات الذهان (تستخدم لعلاج بعض الاضطرابات النفسية)</p><p dir="RTL">&bull; ميثوتريكسات (يستخدم لعلاج التهاب المفاصل الروماتويدي والصدفية وسرطان الدم)</p><p dir="RTL">&bull; كاربامازيبين (يستخدم لعلاج الصرع / النوبات وبعض أشكال الألم أو الاكتئاب)</p><p dir="RTL">&bull; الباربيتورات (المستخدمة في علاج الصرع / النوبات وبعض اضطرابات النوم)</p><p dir="RTL">&bull; سيكلوسبورين وتاكروليموس (يستخدمان لتثبيط الجهاز المناعي على سبيل المثال بعد عمليات الزرع)</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تناول <strong>ريجوريكسا</strong> بجرعة منخفضة مع حمض أسيتيل الساليسيليك (الأسبرين) &nbsp;(75 مجم أو أقل يوميًا). اطلب من طبيبك النصيحة قبل تناول كلا الدواءين معًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملاً أو مرضعة ، تعتقدين أنك حامل أو تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>الحمل</u></strong></p><p dir="RTL">يجب عدم استخدام <strong>ريجوريكسا</strong> من قبل النساء الحوامل أو اللائي يمكن أن يحملن (أي النساء اللائي يحتمل أن يحملن ولا يستخدمن وسائل منع الحمل المناسبة) أثناء العلاج المستمر. إذا أصبحتِ حاملاً أثناء العلاج بـ<strong>ريجوريكسا</strong>، يجب عليك التوقف عن العلاج والاتصال بطبيبك للحصول على علاج بديل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الرضاعة الطبيعية</u></strong></p><p dir="RTL">يجب عدم استخدام <strong>ريجوريكسا</strong> أثناء الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الخصوبة</u></strong></p><p dir="RTL">مضادات الالتهاب غير الستيرويدية ، بما في ذلك <strong>ريجوريكسا</strong>، قد تجعل الحمل أكثر صعوبة. يجب أن تخبري طبيبك إذا كنت تخططين للحمل أو إذا كنت تعانين من مشاكل في الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يجب أن تكون على دراية بكيفية تفاعلك مع <strong>ريجوريكسا</strong> قبل القيادة أو تشغيل الآلات. إذا شعرت بالدوار أو النعاس بعد تناول <strong>ريجوريكسا</strong>، فلا يجوز القيادة أو تشغيل الآلات حتى تزول هذه التأثيرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي ريجوريكسا على اللاكتوز</strong></p><p>يحتوي <strong>ريجوريكسا</strong> على اللاكتوز (نوع من السكر). إذا أخبرك طبيبك أنك لا تتحمل بعض السكريات، فاتصل بطبيبك قبل تناول هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا. إذا كنت تعتقد أو تشعر أن تأثير <strong>ريجوريكسا </strong>قوي جدًا أو ضعيف جدًا، تحدث إلى طبيبك أو الصيدلي.</p><p dir="RTL">سيخبرك طبيبك بالجرعة التي يجب أن تتناولها. نظرًا لأن مخاطر الآثار الجانبية المرتبطة بمشاكل القلب قد تزداد مع الجرعة ومدة الاستخدام، فمن المهم أن تستخدم أقل جرعة تتحكم في ألمك ويجب ألا تتناول <strong>ريجوريكسا </strong>لفترة أطول من اللازم للتحكم في الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستعمال:</strong></p><p dir="RTL"><strong>ريجوريكسا </strong>للاستخدام عن طريق الفم. يمكن تناول الكبسولات في أي وقت من اليوم مع الطعام أو بدونه. ومع ذلك ، حاول أن تأخذ كل جرعة من <strong>ريجوريكسا </strong>في نفس الوقت كل يوم.</p><p dir="RTL">اتصل بطبيبك في غضون أسبوعين من بدء العلاج إذا لم تجد أي فائدة.</p><p dir="RTL"><u>الجرعة الموصى بها هي:</u></p><p dir="RTL"><strong>بالنسبة لمرض التهاب العظمي المفصلي</strong> ، فإن الجرعة الموصى بها هي 200 مجم كل يوم ، ويزيدها طبيبك إلى 400 مجم كحد أقصى ، إذا لزم الأمر.</p><p dir="RTL">الجرعة عادة هي:</p><p dir="RTL">&bull; كبسولة واحدة 200 مجم مرة في اليوم</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بالنسبة لالتهاب المفاصل الروماتويدي</strong> ، الجرعة الموصى بها هي 200 مجم كل يوم ، ويزيدها طبيبك إلى 400 مجم كحد أقصى ، إذا لزم الأمر.</p><p dir="RTL">الجرعة عادة هي:</p><p dir="RTL">&bull; كبسولة واحدة 200 مجم مرة في اليوم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بالنسبة لالتهاب الفقار اللاصق</strong>، فإن الجرعة الموصى بها هي 200 مجم كل يوم ، ويزيدها طبيبك إلى 400 مجم كحد أقصى ، إذا لزم الأمر.</p><p dir="RTL">الجرعة عادة هي:</p><p dir="RTL">&bull; كبسولة واحدة 200 مجم مرة في اليوم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل الكلى أو الكبد</strong>: تأكد من أن طبيبك يعرف ما إذا كنت تعاني من مشاكل في الكبد أو الكلى حيث قد تحتاج إلى جرعة أقل.</p><p dir="RTL"><strong>كبار السن ، وخاصة أولئك الذين يقل وزنهم عن 50 كجم</strong>: إذا كان عمرك يزيد عن 65 عامًا وخاصة إذا كان وزنك أقل من 50 كجم ، فقد يرغب طبيبك في مراقبتك عن كثب.</p><p dir="RTL">يجب ألا تتناول أكثر من 400 مجم يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدم في الأطفال</strong></p><p dir="RTL"><strong>ريجوريكسا </strong>مخصص للبالغين فقط ، وليس للأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت ريجوريكسا أكثر مما يجب</strong></p><p dir="RTL">لا يجب أن تأخذ كبسولات أكثر مما يخبرك طبيبك بذلك. إذا تناولت الكثير من الكبسولات، فاتصل بطبيبك أو الصيدلي أو المستشفى وخذ الدواء معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تأخذ</strong> <strong>ريجوريكسا</strong></p><p dir="RTL">إذا نسيت تناول كبسولة، فتناولها حالما تتذكرها. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول ريجوريكسا</strong></p><p dir="RTL">قد يؤدي إيقاف علاجك بـ <strong>ريجوريكسا </strong>فجأة إلى تفاقم الأعراض. لا تتوقف عن تناول <strong>ريجوريكسا </strong>ما لم يخبرك طبيبك بذلك. قد يخبرك طبيبك بتقليل الجرعة على مدى بضعة أيام قبل التوقف تمامًا.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لوحظت الآثار الجانبية المذكورة أدناه في مرضى التهاب المفاصل الذين تناولوا ريجوريكسا. الآثار الجانبية المميزة بعلامة النجمة (*) مذكورة أدناه في الترددات الأعلى التي حدثت في المرضى الذين تناولوا ريجوريكسا للوقاية من أورام القولون. أخذ المرضى في هذه الدراسات ريجوريكسا بجرعات عالية ولمدة طويلة.</strong></p><p dir="RTL"><strong>في حالة حدوث أي مما يلي ، توقف عن تناول ريجوريكسا وأخبر طبيبك على الفور:</strong></p><p dir="RTL"><strong>اذا عانيت:</strong></p><p dir="RTL">- رد فعل تحسسي مثل طفح جلدي ، انتفاخ في الوجه ، صفير أو صعوبة في التنفس</p><p dir="RTL">- مشاكل في القلب مثل آلام الصدر</p><p dir="RTL">- ألم شديد في المعدة أو أي علامة على حدوث نزيف في المعدة أو الأمعاء ، مثل خروج براز أسود أو ملطخ بالدم أو قيء دم</p><p dir="RTL">- رد فعل جلدي مثل طفح جلدي أو تقرحات أو تقشر في الجلد</p><p dir="RTL">- فشل الكبد (قد تشمل الأعراض الغثيان (الشعور بالمرض) ، الإسهال ، اليرقان (تبدو بشرتك أو بياض عينيك صفراء)).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا: قد تصيب أكثر من &nbsp;شخص &nbsp;واحد من 10 أشخاص</strong></p><p dir="RTL">&bull; ارتفاع ضغط الدم ، بما في ذلك تفاقم ارتفاع ضغط الدم الحالي *</p><p dir="RTL"><strong>شائعة: قد تظهر &nbsp;لدى 1شخص من كل 10 أشخاص</strong></p><p dir="RTL">&bull; نوبة قلبية*</p><p dir="RTL">&bull; تراكم السوائل مع تورم الكاحلين والساقين و / أو اليدين</p><p dir="RTL">&bull; التهابات المسالك البولية</p><p dir="RTL">&bull; ضيق التنفس * ، التهاب الجيوب الأنفية (التهاب الجيوب الأنفية ، التهاب الجيوب الأنفية ، انسداد الجيوب الأنفية المؤلمة) ، انسداد أو سيلان الأنف ، التهاب الحلق ، السعال ، نزلات البرد ، أعراض تشبه أعراض الأنفلونزا</p><p dir="RTL">&bull; الدوخة وصعوبة النوم</p><p dir="RTL">&bull; قيء * ، آلام في المعدة ، إسهال ، عسر هضم ، ريح</p><p dir="RTL">&bull; طفح جلدي ، حكة</p><p dir="RTL">&bull; تصلب العضلات</p><p dir="RTL">&bull; صعوبة البلع *</p><p dir="RTL">&bull; صداع الراس</p><p dir="RTL">&bull; الغثيان (الشعور بالغثيان)</p><p dir="RTL">&bull; ألم في المفاصل</p><p dir="RTL">&bull; تفاقم الحساسية الموجودة</p><p dir="RTL">&bull; إصابة عرضية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تظهر &nbsp;لدى 1 شخص من كل 100 شخص</strong></p><p dir="RTL">&bull; سكتة دماغية*</p><p dir="RTL">&bull; فشل القلب ، الخفقان (الوعي بضربات القلب) ، سرعة دقات القلب</p><p dir="RTL">&bull; شذوذ في اختبارات الدم المتعلقة بالكبد</p><p dir="RTL">&bull; شذوذ في اختبارات الدم المتعلقة بالكلى</p><p dir="RTL">&bull; فقر الدم (التغيرات في خلايا الدم الحمراء التي يمكن أن تسبب التعب وضيق التنفس)</p><p dir="RTL">&bull; القلق ، والاكتئاب ، والتعب ، والنعاس ، والوخز (دبابيس وإبر)</p><p dir="RTL">&bull; ارتفاع مستويات البوتاسيوم في نتائج فحص الدم (يمكن أن يسبب الغثيان (الشعور بالغثيان) ، والتعب ، وضعف العضلات أو خفقان القلب)</p><p dir="RTL">&bull; ضعف أو تشوش الرؤية ، طنين في الأذنين ، ألم في الفم وتقرحات ، صعوبة في السمع *</p><p dir="RTL">&bull; الإمساك ، التجشؤ ، التهاب المعدة (عسر الهضم ، آلام المعدة أو القيء) ، تفاقم التهاب المعدة أو الأمعاء</p><p dir="RTL">&bull; تشنجات الساق</p><p dir="RTL">&bull; طفح جلدي مثير للحكة شري</p><p dir="RTL">&bull; التهاب العين</p><p dir="RTL">&bull; صعوبة التنفس</p><p dir="RTL">&bull; تغير لون الجلد (كدمات)</p><p dir="RTL">&bull; ألم في الصدر (ألم عام لا علاقة له بالقلب)</p><p dir="RTL">&bull; انتفاخ الوجه</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة: قد تظهر لدى حتى 1 شخص من كل 1000 شخص</strong></p><p dir="RTL">&bull; القرحة (نزيف) في المعدة أو المريء أو الأمعاء. أو تمزق الأمعاء (يمكن أن يسبب آلام في المعدة ، حمى ، غثيان ، قيء ، انسداد معوي) ، براز داكن أو أسود ، التهاب البنكرياس (يمكن أن يؤدي إلى آلام في المعدة) ، التهاب المريء (المريء)</p><p dir="RTL">&bull; انخفاض مستويات الصوديوم في الدم (حالة تعرف باسم نقص صوديوم الدم)</p><p dir="RTL">&bull; انخفاض عدد خلايا الدم البيضاء (التي تساعد على حماية الجسم من العدوى) أو الصفائح الدموية (زيادة فرصة حدوث نزيف أو كدمات)</p><p dir="RTL">&bull; صعوبة تنسيق الحركات العضلية</p><p dir="RTL">&bull; الشعور بالارتباك ، تغير في طعم الأشياء</p><p dir="RTL">&bull; زيادة الحساسية للضوء</p><p dir="RTL">&bull; تساقط الشعر</p><p dir="RTL">&bull; الهلوسة</p><p dir="RTL">&bull; نزيف في العين</p><p dir="RTL">&bull; رد فعل حاد قد يؤدي إلى التهاب الرئة</p><p dir="RTL">&bull; اضطراب نبضات القلب</p><p dir="RTL">&bull; تدفق مائى - صرف</p><p dir="RTL">&bull; تجلط الدم في الأوعية الدموية في الرئتين. قد تشمل الأعراض ضيق التنفس المفاجئ ، وآلام حادة عند التنفس أو هبوط</p><p dir="RTL">&bull; نزيف في المعدة أو الأمعاء (يمكن أن يؤدي إلى دم في البراز أو القيء) ، التهاب الأمعاء أو القولون</p><p dir="RTL">&bull; التهاب الكبد الحاد (التهاب الكبد). قد تشمل الأعراض الغثيان (الشعور بالغثيان) ، والإسهال ، واليرقان (تغير لون الجلد أو العينين إلى الأصفر) ، والبول الداكن ، والبراز الشاحب ، والنزيف بسهولة ، والحكة أو القشعريرة</p><p dir="RTL">&bull; الفشل الكلوي الحاد</p><p dir="RTL">&bull; اضطرابات الدورة الشهرية</p><p dir="RTL">&bull; تورم الوجه أو الشفتين أو الفم أو اللسان أو الحلق أو صعوبة البلع</p><p dir="RTL"><strong>نادر جدًا: قد تظهر لدى 1 شخص من كل 10000 شخص</strong></p><p dir="RTL">&bull; تفاعلات حساسية خطيرة (بما في ذلك صدمة الحساسية القاتلة)</p><p dir="RTL">&bull; الأمراض الجلدية الخطيرة مثل متلازمة ستيفنز جونسون والتهاب الجلد التقشري وانحلال البشرة النخري السمي (يمكن أن يسبب طفح جلدي أو تقرحات أو تقشير الجلد) وبثور طفيلي حاد معمم (تشمل الأعراض احمرار الجلد مع وجود مناطق منتفخة مغطاة بالعديد من البثور الصغيرة)</p><p dir="RTL">&bull; رد فعل تحسسي متأخر مع أعراض محتملة مثل الطفح الجلدي وتورم الوجه والحمى وتورم الغدد ونتائج الاختبارات غير الطبيعية (على سبيل المثال ، الكبد وخلايا الدم (فرط الحمضات ، وهو نوع من ارتفاع عدد خلايا الدم البيضاء))</p><p dir="RTL">&bull; نزيف داخل المخ يسبب الموت</p><p dir="RTL">&bull; التهاب السحايا (التهاب الغشاء المحيط بالمخ والنخاع الشوكي)</p><p dir="RTL">&bull; فشل الكبد وتلف الكبد والتهاب الكبد الحاد (التهاب الكبد الخاطف) (أحيانًا يكون مميتًا أو يتطلب زراعة كبد). قد تشمل الأعراض الغثيان (الشعور بالغثيان) ، والإسهال ، واليرقان (تغير لون الجلد أو العينين إلى الأصفر) ، والبول الداكن ، والبراز الشاحب ، والنزيف بسهولة ، والحكة أو القشعريرة</p><p dir="RTL">&bull; مشاكل الكبد (مثل الركود الصفراوي والتهاب الكبد الصفراوي ، والتي قد تكون مصحوبة بأعراض مثل تغير لون البراز والغثيان واصفرار الجلد أو العينين)</p><p dir="RTL">&bull; التهاب الكلى ومشاكل أخرى في الكلى (مثل المتلازمة الكلوية ومرض التغيير الأدنى ، والتي قد تكون مصحوبة بأعراض مثل احتباس الماء (الوذمة) ، والبول الرغوي ، والتعب وفقدان الشهية)</p><p dir="RTL">&bull; تفاقم الصرع (احتمال حدوث نوبات متكررة و / أو شديدة)</p><p dir="RTL">&bull; انسداد الشريان أو الوريد في العين مما يؤدي إلى فقدان جزئي أو كامل للرؤية</p><p dir="RTL">&bull; التهاب الأوعية الدموية (يمكن أن يسبب الحمى والآلام والبقع الأرجوانية على الجلد)</p><p dir="RTL">&bull; انخفاض في عدد خلايا الدم الحمراء والبيضاء والصفائح الدموية (قد يسبب التعب وسهولة الكدمات ونزيف الأنف المتكرر وزيادة خطر الإصابة بالعدوى)</p><p dir="RTL">&bull; آلام العضلات وضعفها</p><p dir="RTL">&bull; ضعف حاسة الشم</p><p dir="RTL">&bull; فقدان التذوق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف: لا يمكن تقدير التردد من البيانات المتاحة</strong></p><p dir="RTL">&bull; انخفاض الخصوبة عند الإناث ، والذي يمكن عكسه عادة عند التوقف عن تناول الدواء</p><p dir="RTL"><strong>في الدراسات السريرية غير المرتبطة بالتهاب المفاصل أو غيرها من حالات التهاب المفاصل ، حيث تم تناول ريجوريكسا بجرعات 400 ملغ يوميًا لمدة تصل إلى 3 سنوات ، لوحظت الآثار الجانبية الإضافية التالية:</strong></p><p dir="RTL"><strong>شائعة: قد تظهر لدى حتى 1 شخص من كل 10 أشخاص</strong></p><p dir="RTL">&bull; مشاكل القلب: الذبحة الصدرية (ألم في الصدر)</p><p dir="RTL">&bull; مشاكل المعدة: متلازمة القولون العصبي (يمكن أن تشمل آلام المعدة ، والإسهال ، وعسر الهضم ، والرياح)</p><p dir="RTL">&bull; حصوات الكلى (التي قد تؤدي إلى آلام في المعدة أو الظهر ، دم في البول) ، صعوبة في التبول</p><p dir="RTL">&bull; زيادة الوزن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: قد تظهر لدى 1 شخص من كل 100 شخص</strong></p><p dir="RTL">&bull; تجلط الأوردة العميقة (جلطة دموية عادة في الساق ، والتي قد تسبب الألم أو التورم أو احمرار ربلة الساق أو مشاكل في التنفس)</p><p dir="RTL">&bull; مشاكل في المعدة: التهاب في المعدة (يمكن أن يسبب تهيج وقرحة المعدة والأمعاء)</p><p dir="RTL">&bull; كسر في الطرف السفلي</p><p dir="RTL">&bull; القوباء المنطقية ، والتهاب الجلد ، والأكزيما (الطفح الجلدي الجاف والحكة) ، والالتهاب الرئوي (التهاب في الصدر (سعال محتمل ، وحمى ، وصعوبة في التنفس))</p><p dir="RTL">&bull; عوائم في العين و التي تسبب عدم وضوح الرؤية أو ضعفها ، والدوار بسبب مشاكل في الأذن الداخلية ، وجع و التهاب ، او &nbsp;نزيف اللثة ، وتقرحات الفم</p><p dir="RTL">&bull; كثرة التبول ليلاً ، نزيف من البواسير ، حركات أمعاء متكررة</p><p dir="RTL">&bull; كتل دهنية في الجلد أو في أي مكان آخر ، كيس عقدي (تورمات غير مؤذية في أو حول المفاصل والأوتار في اليد أو القدم) ، صعوبة في الكلام ، نزيف غير طبيعي أو شديد من المهبل ، ألم في الثدي</p><p dir="RTL">&bull; ارتفاع مستويات الصوديوم في نتائج فحص الدم</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من هذا الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخزن في مغلفها الأصلي. يخزن في درجة حرارة أقل من 30 &deg;م</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم تناول الدواء اذا لاحظت علامات تلف واضحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب التخلص من أي أدوية عبر مياه الصرف الصحي أو&nbsp;النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. سوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة في <strong>ريجوريكسا</strong> هي السيليكوكسيب. كل كبسولة تحتوي على200 ملجم السيليكوكسيب.</p><p dir="RTL"><strong>المكونات الأخرى هي:</strong></p><p dir="RTL">المواد غير الفعالة في الكبسولة الواحد:</p><p dir="RTL">كبريتات لوريل الصوديوم ، بوفيدون ،&nbsp; اللاكتوز أحادي الهيدرات ، كروس كارميللوز الصوديوم ، صوديوم سترايل الفيوماريت.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ريجوريكسا 200 ملجم هو كبسولة ذات غطاء و جسم أبيض غير شفاف ، &nbsp;تحمل شريطين ذهبيين اللون ، مطبوع على الغطاء &quot;</strong><strong>JS14</strong><strong>&quot; و مطبوع على الجسم &quot;200&quot;.</strong></p><p dir="RTL"><strong>ريجوريكسا 200 ملجم متوفر في عبوات تحتوي على 20 كبسولة. </strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ألفا فارما</p><p dir="RTL">مدينة الملك عيد الله الإقتصلدية - المملكة العريية السعودية</p><p dir="RTL">regulatory@alphapharma.com.sa: البريد الإلكتروني</p><p dir="RTL">تلفون: 00966122129013</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            6/2021

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rigorixa 200 mg capsules, hard
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 200 mg celecoxib.
Excipient with known effect
Lactose (each capsule contains 47.061 mg lactose monohydrate; see section 4.4).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Rigorixa 200 mg: Opaque White with two gold band, imprint with JS14 in the cap, and 200 in the body.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rigorixa is indicated in adults for the symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.</p><p>The decision to prescribe a selective cyclooxygenase-2 (COX-2) inhibitor should be based on an assessment of the individual patient&#39;s overall risks (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Posology</u></em></strong></p><p><strong><u>&nbsp;</u></strong></p><p>As the cardiovascular (CV) risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1).</p><p><strong><em>Osteoarthritis</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The usual recommended daily dose is 200 mg taken once daily or in two divided doses. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p><em>&nbsp;</em></p><p><strong><em>Rheumatoid arthritis</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The initial recommended daily dose is 200 mg taken in two divided doses. The dose may, if needed, later be increased to 200 mg twice daily. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p><strong><em>Ankylosing spondylitis</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The recommended daily dose is 200 mg taken once daily or in two divided doses. In a few patients, with insufficient relief from symptoms, an increased dose of 400 mg once daily or in two divided doses may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p>The maximum recommended daily dose is 400 mg for all indications.</p><p>&nbsp;</p><p><strong><em><u>Special populations</u></em></strong></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Elderly</em></strong></p><p>As in younger adults, 200 mg per day should be used initially. The dose may, if needed, later be increased to 200 mg twice daily. Particular caution should be exercised in elderly with a body weight less than 50 kg (see sections 4.4 and 5.2).</p><p><strong><em>Paediatric population</em></strong></p><p>Celecoxib is not indicated for use in children.</p><p><strong><em>CYP2C9 poor metabolisers</em></strong></p><p>Patients who are known, or suspected to be CYP2C9 poor metabolisers based on genotyping or previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution as the risk of dose-dependent adverse effects is increased. Consider reducing the dose to half the lowest recommended dose (see section 5.2).</p><p><strong><em>Hepatic impairment</em></strong></p><p>Treatment should be initiated at half the recommended dose&nbsp;in patients with established&nbsp;moderate liver impairment with a serum&nbsp;albumin of&nbsp;25-35 g/l. Experience in such patients is limited to cirrhotic patients (see sections 4.3, 4.4 and 5.2).</p><p><strong><em>Renal impairment</em></strong></p><p>Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore such patients should be treated with caution (see sections 4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><strong><em><u>Method of administration</u></em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em>Oral use</em></strong></p><p>Rigorixa may be taken with or without food. For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce, rice gruel, yogurt or mashed banana. To do so, the entire capsule contents must be carefully emptied onto a level teaspoon of cool or room temperature applesauce, rice gruel, yogurt or mashed banana and should be ingested immediately with 240 ml of water. The sprinkled capsule contents on applesauce, rice gruel or yogurt are stable for up to 6 hours under refrigerated conditions (2-8&deg;C). The sprinkled capsule contents on mashed banana should not be stored under refrigerated conditions and should be ingested immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Known hypersensitivity to sulfonamides.
Active peptic ulceration or gastrointestinal (GI) bleeding.
Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.
In pregnancy and in women of childbearing potential unless using an effective method of contraception (see section 4.6). Celecoxib has been shown to cause malformations in the two animal species studied (see sections 4.6 and 5.3). The potential for human risk in pregnancy is unknown but cannot be excluded.
Breast-feeding (see sections 4.6 and 5.3).
Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
Patients with estimated creatinine clearance <30 ml/min.
Inflammatory bowel disease.
Congestive heart failure (NYHA II-IV).
Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Gastrointestinal (GI) effects</u></strong></p><p>Upper and lower gastrointestinal complications (perforations, ulcers or bleedings [PUBs]), some of them resulting in fatal outcome, have occurred in patients treated with celecoxib. Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or antiplatelet drugs (such as acetylsalicylic acid), or glucocorticoids concomitantly, patients using alcohol, or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.</p><p>There is further increase in the risk of gastrointestinal adverse effects for celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses). A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid&nbsp;<em>vs</em>. NSAIDs + acetylsalicylic acid has not been demonstrated in long-term clinical trials (see section 5.1).</p><p><strong><u>Concomitant NSAID use</u></strong></p><p>The concomitant use of celecoxib and a non-aspirin NSAID should be avoided.</p><p><strong><u>Cardiovascular effects</u></strong></p><p>Increased number of serious cardiovascular (CV) events, mainly myocardial infarction, has been found in a long-term placebo-controlled study in subjects with sporadic adenomatous polyps treated with celecoxib at doses of 200 mg BID and 400 mg BID compared to placebo (see section 5.1).</p><p>As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. NSAIDs, including COX-2 selective inhibitors, have been associated with increased risk of cardiovascular and thrombotic adverse events when taken long term. The exact magnitude of the risk associated with a single dose has not been determined, nor has the exact duration of therapy associated with increased risk. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).</p><p>Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with celecoxib after careful consideration (see section 5.1).</p><p>COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects. Therefore, antiplatelet therapies should not be discontinued (see section 5.1).</p><p><strong><u>Fluid retention and oedema</u></strong></p><p>As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention and oedema have been observed in patients taking celecoxib. Therefore, celecoxib should be used with caution in patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any other reason, since prostaglandin inhibition may result in deterioration of renal function and fluid retention. Caution is also required in patients taking diuretic treatment or otherwise at risk of hypovolaemia.</p><p><strong><u>Hypertension</u></strong></p><p>As with all NSAIDS, celecoxib can lead to the onset of new hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. Therefore, blood pressure should be monitored closely during the initiation of therapy with celecoxib and throughout the course of therapy.</p><p><strong><u>Hepatic and renal effects</u></strong></p><p>Compromised renal or hepatic function and especially cardiac dysfunction are more likely in the elderly and therefore medically appropriate supervision should be maintained.</p><p>NSAIDs, including celecoxib, may cause renal toxicity. Clinical trials with celecoxib have shown renal effects similar to those observed with comparator NSAIDs. Patients at greatest risk for renal toxicity are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, angiotensin converting enzyme (ACE)-inhibitors, angiotensin II receptor antagonists, and the elderly (see section 4.5). Such patients should be carefully monitored while receiving treatment with celecoxib.</p><p>Some cases of severe hepatic reactions, including fulminant hepatitis (some with fatal outcome), liver necrosis and, hepatic failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. Among the cases that reported time to onset, most of the severe adverse hepatic events developed within one month after initiation of celecoxib treatment (see section 4.8).</p><p>If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of celecoxib therapy should be considered.</p><p><strong><u>CYP2D6 inhibition</u></strong></p><p>Celecoxib inhibits CYP2D6. Although it is not a strong inhibitor of this enzyme, a dose reduction may be necessary for individually dose-titrated medicinal products that are metabolised by CYP2D6 (see section 4.5).</p><p><u>&nbsp;</u></p><p><strong><u>CYP2C9 poor metabolisers</u></strong></p><p>Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2).</p><p><strong><u>Skin and systemic hypersensitivity reactions</u></strong></p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of celecoxib (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (including anaphylaxis, angioedema and drug rash with eosinophilia and systemic symptoms (DRESS), or hypersensitivity syndrome), have been reported in patients receiving celecoxib (see section 4.8). Patients with a history of sulfonamide allergy or any drug allergy may be at greater risk of serious skin reactions or hypersensitivity reactions (see section 4.3). Celecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p><strong><u>General</u></strong></p><p>Celecoxib may mask fever and other signs of inflammation.</p><p><strong><u>Use with oral anticoagulants</u></strong></p><p>In patients on concurrent therapy with warfarin, serious bleeding events, some of them fatal, have been reported. Increased prothrombin time (INR) with concurrent therapy has been reported. Therefore, this should be closely monitored in patients receiving warfarin/coumarin-type oral anticoagulants, particularly when therapy with celecoxib is initiated or celecoxib dose is changed (see section 4.5). Concomitant use of anticoagulants with NSAIDS may increase the risk of bleeding. Caution should be exercised when combining celecoxib with warfarin or other oral anticoagulants, including novel anticoagulants (e.g. apixaban, dabigatran, and rivaroxaban).</p><p><strong><u>Excipients</u></strong></p><p>Rigorixa 200 mg capsules contain lactose (47.061 mg). Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pharmacodynamic interactions</u></strong></p><p><strong><em>Anticoagulants</em></strong></p><p>Anticoagulant activity should be monitored particularly in the first few days after initiating or changing the dose of celecoxib in patients receiving warfarin or other anticoagulants since these patients have an increased risk of bleeding complications. Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with celecoxib is initiated or the dose of celecoxib is changed (see section 4.4). Bleeding events in association with increases in prothrombin time have been reported, predominantly in the elderly, in patients receiving celecoxib concurrently with warfarin, some of them fatal.</p><p><strong><em>Anti-hypertensives</em></strong></p><p>NSAIDs may reduce the effect of anti-hypertensive medicinal products including ACE-inhibitors, angiotensin II receptor antagonists, diuretics and beta-blockers. As for NSAIDs, the risk of acute renal insufficiency, which is usually reversible, may be increased in some patients with compromised renal function (e.g. dehydrated patients, patients on diuretics, or elderly patients) when ACE-inhibitors, angiotensin II receptor antagonists, and/or diuretics are combined with NSAIDs, including celecoxib (see section 4.4). Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>In a 28-day clinical study in patients with lisinopril-controlled Stage I and II hypertension, administration of celecoxib 200 mg BID resulted in no clinically significant increases, when compared to placebo treatment, in mean daily systolic or diastolic blood pressure as determined using 24-hour ambulatory blood pressure monitoring. Among patients treated with celecoxib 200 mg BID, 48 % were considered unresponsive to lisinopril at the final clinic visit (defined as either cuff diastolic blood pressure &gt;90 mmHg or cuff diastolic blood pressure increased &gt;10 % compared to baseline), compared to 27 % of patients treated with placebo; this difference was statistically significant.</p><p><strong><em>Ciclosporin and tacrolimus</em></strong></p><p>Co-administration of NSAIDs and ciclosporin or tacrolimus may increase the nephrotoxic effect of ciclosporin or tacrolimus, respectively. Renal function should be monitored when celecoxib and any of these medicinal products are combined.</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p><strong><em>Acetylsalicylic acid</em></strong></p><p>Celecoxib can be used with low-dose acetylsalicylic acid but is not a substitute for acetylsalicylic acid for CV prophylaxis. In the submitted studies, as with other NSAIDs, an increased risk of gastrointestinal ulceration or other gastrointestinal complications compared to use of celecoxib alone was shown for concomitant administration of low-dose acetylsalicylic acid (see section 5.1).</p><p><strong><u>Pharmacokinetic interactions</u></strong></p><p><strong><em>Effects of celecoxib on other medicinal products</em></strong></p><p><strong><em><u>CYP2D6 inhibition</u></em></strong></p><p>Celecoxib is an inhibitor of CYP2D6. The plasma concentrations of medicinal products that are substrates of this enzyme may be increased when celecoxib is used concomitantly. Examples of medicinal products which are metabolised by CYP2D6 are antidepressants (tricyclics and SSRIs), neuroleptics, anti-arrhythmic medicinal products, etc. The dose of individually dose-titrated CYP2D6 substrates may need to be reduced when treatment with celecoxib is initiated or increased if treatment with celecoxib is terminated.</p><p>Concomitant administration of celecoxib 200 mg twice daily resulted in 2.6-fold and 1.5-fold increases in plasma concentrations of dextromethorphan and metoprolol (CYP2D6 substrates), respectively. These increases are due to celecoxib inhibition of the CYP2D6 substrate metabolism.</p><p><strong><em><u>CYP2C19 inhibition</u></em></strong></p><p><em>In vitro</em>&nbsp;studies have shown some potential for celecoxib to inhibit CYP2C19 catalysed metabolism. The clinical significance of this in vitro finding is unknown. Examples of medicinal products which are metabolised by CYP2C19 are diazepam, citalopram and imipramine.</p><p><strong><em><u>Methotrexate</u></em></strong></p><p>In patients with rheumatoid arthritis celecoxib had no statistically significant effect on the pharmacokinetics (plasma or renal clearance) of methotrexate (in rheumatologic doses). However, adequate monitoring for methotrexate-related toxicity should be considered when combining these two medicinal products.</p><p><strong><em><u>Lithium</u></em></strong></p><p>In healthy subjects, co-administration of celecoxib 200 mg twice daily with 450 mg twice daily of lithium resulted in a mean increase in C<sub>max</sub>&nbsp;of 16 % and in area under the curve (AUC) of 18 % of lithium. Therefore, patients on lithium treatment should be closely monitored when celecoxib is introduced or withdrawn.</p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><strong><em><u>Oral contraceptives</u></em></strong></p><p>In an interaction study, celecoxib had no clinically relevant effects on the pharmacokinetics of oral contraceptives (1 mg norethisterone /35 micrograms ethinylestradiol).</p><p><strong><em><u>Glibenclamide/tolbutamide</u></em></strong></p><p>Celecoxib does not affect the pharmacokinetics of tolbutamide (CYP2C9 substrate), or glibenclamide to a clinically relevant extent.</p><p><strong><em>Effects of other medicinal products on celecoxib</em></strong></p><p><strong><em><u>CYP2C9 poor metabolisers</u></em></strong></p><p>In individuals who are CYP2C9 poor metabolisers and demonstrate increased systemic exposure to celecoxib, concomitant treatment with CYP2C9 inhibitors such as fluconazole could result in further increases in celecoxib exposure. Such combinations should be avoided in known CYP2C9 poor metabolisers (see sections 4.2 and 5.2).</p><p><strong><em><u>CYP2C9 inhibitors and inducers</u></em></strong></p><p>Since celecoxib is predominantly metabolised by CYP2C9 it should be used at half the recommended dose in patients receiving fluconazole. Concomitant use of 200 mg single dose of celecoxib and 200 mg once daily of fluconazole, a potent CYP2C9 inhibitor, resulted in a mean increase in celecoxib C<sub>max</sub>&nbsp;of 60% and in AUC of 130%. Concomitant use of inducers of CYP2C9 such as rifampicin, carbamazepine and barbiturates may reduce plasma concentrations of celecoxib.</p><p><strong><em><u>Ketoconazole and antacids</u></em></strong></p><p>Ketoconazole or antacids have not been observed to affect the pharmacokinetics of celecoxib.</p><p><strong><em>Paediatric population</em></strong></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em><u>Pregnancy</u></em></strong></p><p>Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see sections 4.3 and 5.3). Inhibition of prostaglandin synthesis might adversely affect pregnancy. Data from epidemiological studies suggest an increased risk of spontaneous abortion after use of prostaglandin synthesis inhibitors in early pregnancy. The potential for human risk in pregnancy is unknown, but cannot be excluded. Celecoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.</p><p>During the second or third trimester of pregnancy, NSAIDs including celecoxib may cause fetal renal dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe cases. Such effects may occur shortly after treatment initiation and are usually reversible.</p><p>Celecoxib is contraindicated in pregnancy and in women who can become pregnant (see sections 4.3 and 4.4). If a woman becomes pregnant during treatment, celecoxib should be discontinued.</p><p><strong><em>&nbsp;<u>Breastfeeding</u></em></strong></p><p>Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma. Administration of celecoxib to a limited number of lactating women has shown a very low transfer of celecoxib into breast milk. Women who take Rigorixa should not breastfeed.<strong><em> </em></strong></p><p><strong><em><u>Fertility</u></em></strong></p><p>Based on the mechanism of action, the use of NSAIDs, including celecoxib, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience dizziness, vertigo or somnolence while taking Rigorixa should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are listed by system organ class and ranked by frequency in&nbsp;<strong>Table 1</strong>, reflecting data from the following sources:</p><p>&bull; Adverse reactions reported in osteoarthritis patients and rheumatoid arthritis patients at incidence rates greater than 0.01 % and greater than those reported for placebo during 12 placebo- and/or active-controlled clinical trials of duration up to 12 weeks at celecoxib daily doses from 100 mg up to 800 mg. In additional studies using non-selective NSAID comparators, approximately 7400 arthritis patients have been treated with celecoxib at daily doses up to 800 mg, including approximately 2300 patients treated for 1 year or longer. The adverse reactions observed with celecoxib in these additional studies were consistent with those for osteoarthritis and rheumatoid arthritis patients listed in&nbsp;<strong>Table 1</strong>.</p><p>&bull; Adverse reactions reported at incidence rates greater than placebo for subjects treated with celecoxib 400 mg daily in long-term polyp prevention trials of duration up to 3 years (the Adenoma Prevention with Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials; see section 5.1, Cardiovascular safety &ndash; long-term studies involving patients with sporadic adenomatous polyps).</p><p>&bull; Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period in which an estimated &gt;70 million patients were treated with celecoxib (various doses, durations, and indications). Even though these were identified as reactions from post-marketing reports, trial data was consulted to estimate frequency. Frequencies are based on a cumulative meta-analysis with pooling of trials representing exposure in 38102 patients.</p><p><strong>Table&nbsp;1. Adverse drug reactions in celecoxib clinical trials and surveillance experience (MedDRA preferred terms)<sup>1,2</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:745px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="6" style="vertical-align:top"><p><strong>Adverse Drug Reaction Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p>(&ge;1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge;1/100 to &lt;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge;1/1,000 to &lt;1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&ge;1/10,000 to &lt;1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p>(&lt;1/10,000)</p></td><td style="vertical-align:top"><p><strong>Frequency Not Known (cannot be estimated from available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Sinusitis, upper respiratory tract infection, pharyngitis, urinary tract infection</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Leukopenia, thrombo-cytopenia</p></td><td style="vertical-align:top"><p>Pancytopenia<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyper-sensitivity</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic shock<sup>4</sup>, anaphylactic reaction<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety, depression, fatigue</p></td><td style="vertical-align:top"><p>Confusional state, hallucinations<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dizziness, hypertonia, headache<sup>4</sup></p></td><td style="vertical-align:top"><p>Cerebral infarction<sup>1</sup>, paraesthesia, somnolence</p></td><td style="vertical-align:top"><p>Ataxia, dysgeusia</p></td><td style="vertical-align:top"><p>Haemorrhage intracranial (including fatal intracranial haemorrhage)<sup>4</sup>, meningitis aseptic<sup>4</sup>, epilepsy (including aggravated epilepsy)<sup>4</sup>, ageusia<sup>4</sup>, anosmia<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vision blurred, conjunctivitis<sup>4</sup></p></td><td style="vertical-align:top"><p>Eye haemorrhage<sup>4</sup></p></td><td style="vertical-align:top"><p>Retinal artery occlusion<sup>4</sup>, retinal vein occlusion<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus, hypoacusis<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Myocardial infarction<sup>1</sup></p></td><td style="vertical-align:top"><p>Cardiac failure, palpitations, tachycardia</p></td><td style="vertical-align:top"><p>Arrhythmia<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Hyper-tension<sup>1</sup>&nbsp;(including aggravated hyper-tension)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pulmonary embolism<sup>4</sup>, flushing<sup>4</sup></p></td><td style="vertical-align:top"><p>Vasculitis<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic, and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rhinitis, cough, dyspnoea<sup>1</sup></p></td><td style="vertical-align:top"><p>Bronchospasm<sup>4</sup></p></td><td style="vertical-align:top"><p>Pneumonitis<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Nausea<sup>4</sup>, abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting<sup>1</sup>, dysphagia<sup>1</sup></p></td><td style="vertical-align:top"><p>Constipation, gastritis, stomatitis, gastrointestinal inflammation (including aggravation of gastrointestinal inflammation), eructation</p></td><td style="vertical-align:top"><p>Gastro-intestinal haemorrhage<sup>4</sup>, duodenal ulcer, gastric ulcer, oesophageal ulcer, intestinal ulcer, large intestinal ulcer, intestinal perforation, oesophagitis, melaena, pancreatitis, colitis<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatic function abnormal, hepatic enzyme increased (including increased SGOT and SGPT)</p></td><td style="vertical-align:top"><p>Hepatitis<sup>4</sup></p></td><td style="vertical-align:top"><p>Hepatic failure<sup>4</sup>&nbsp;(sometimes fatal or requiring liver transplant), hepatitis fulminant<sup>4</sup>&nbsp;(some with fatal outcome), hepatic necrosis<sup>4</sup>, cholestasis<sup>4</sup>, hepatitis cholestatic<sup>4</sup>, jaundice<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash, pruritus (includes pruritus generalised)</p></td><td style="vertical-align:top"><p>Urticaria, ecchymosis<sup>4</sup></p></td><td style="vertical-align:top"><p>Angioedema<sup>4</sup>, alopecia, photo-sensitivity</p></td><td style="vertical-align:top"><p>Dermatitis exfoliative<sup>4</sup>, erythema multiforme<sup>4</sup>, Stevens-Johnson syndrome<sup>4</sup>, toxic epidermal necrolysis<sup>4</sup>, drug reaction with eosinophilia and systemic symptoms (DRESS)<sup>&nbsp;4</sup>, acute generalised exanthematous pustulosis (AGEP)<sup>4</sup>, dermatitis bullous<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia<sup>4</sup></p></td><td style="vertical-align:top"><p>Muscle spasms (leg cramps)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Myositis<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased, blood urea increased</p></td><td style="vertical-align:top"><p>Renal failure acute<sup>4</sup>, hypo-natraemia<sup>4</sup></p></td><td style="vertical-align:top"><p>Tubulointerstitial nephritis<sup>4</sup>, nephrotic syndrome<sup>4</sup>, glomerulonephritis minimal lesion<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Menstrual disorder<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Infertility female (female fertility decreased)<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administrative site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Influenza-like illness, oedema peripheral/ fluid retention</p></td><td style="vertical-align:top"><p>Face oedema, chest pain<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Injury (accidental injury)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top">&nbsp;</td><td colspan="6" style="vertical-align:top"><p><sup>1</sup>&nbsp;Adverse drug reactions that occurred in polyp prevention trials, representing subjects treated with celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials). The adverse drug reactions listed above for the polyp prevention trials are only those that have been previously recognised in the post-marketing surveillance experience, or have occurred more frequently than in the arthritis trials.</p><p>&nbsp;</p><p><sup>2</sup>&nbsp;Furthermore, the following&nbsp;<em>previously unknown</em>&nbsp;adverse reactions occurred in polyp prevention trials, representing subjects treated with celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials):</p><p>&nbsp;</p><p><strong>Common:</strong>&nbsp;angina pectoris, irritable bowel syndrome, nephrolithiasis, blood creatinine increased, benign prostatic hyperplasia, weight increased.&nbsp;<strong>Uncommon:&nbsp;</strong>helicobacter infection, herpes zoster, erysipelas, bronchopneumonia, labyrinthitis, gingival infection, lipoma, vitreous floaters, conjunctival haemorrhage, deep vein thrombosis, dysphonia, haemorrhoidal haemorrhage, frequent bowel movements, mouth ulceration, allergic dermatitis, ganglion, nocturia, vaginal haemorrhage, breast tenderness, lower limb fracture, blood sodium increased.</p><p>&nbsp;</p><p><sup>3</sup>&nbsp;Women intending to become pregnant are excluded from all trials, thus consultation of the trial database for the frequency of this event was not reasonable.</p><p>&nbsp;</p><p><sup>4</sup>&nbsp;Frequencies are based on cumulative meta-analysis with pooling of trials representing exposure in 38102 patients.</p></td></tr></tbody></table><p>&nbsp;</p><p>In final data (adjudicated) from the APC and PreSAP trials in patients treated with celecoxib 400 mg daily for up to 3 years (pooled data from both trials; see section 5.1 for results from individual trials), the excess rate over placebo for myocardial infarction was 7.6 events per 1,000 patients (uncommon) and there was no excess rate for stroke (types not differentiated) over placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>&nbsp;Reporting of suspected adverse reactions</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong>To Report Any Side Effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>&bull; Fax: +966-11-205-7662</p><p>&bull; Call NPC at +966-11-2038222, Ext 2317-2356-2340</p><p>&bull; SFDA Call Center: 19999</p><p>&bull; E-mail: npc.drug@sfda.gov.sa&nbsp;</p><p>&bull; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&bull; Please contact the relevant competent authority.&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience of overdose. Single doses up to 1200 mg and multiple doses up to 1200 mg twice daily have been administered to healthy subjects for nine days without clinically significant adverse effects. In the event of suspected overdose, appropriate supportive medical care should be provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution of symptomatic treatment. Dialysis is unlikely to be an efficient method of medicinal product removal due to high protein binding.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: Non-steroidal anti-inflammatory and antirheumatic drugs, NSAIDs, Coxibs, ATC code: M01AH01.</p><p><strong><u>Mechanism of action</u></strong></p><p>Celecoxib is an oral, selective, COX-2 inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as&nbsp;<em>ex vivo</em>&nbsp;inhibition of thromboxane B<sub>2</sub>&nbsp;[TxB<sub>2</sub>] formation) was observed in this dose range in healthy volunteers.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in humans but its relevance to ulcer healing has not been established.</p><p>The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.</p><p>Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differs from arylamine sulfonamides (e.g. sulfamethoxizole and other sulfonamide antibiotics).</p><p>A dose-dependent effect on TxB<sub>2</sub>&nbsp;formation has been observed after high doses of celecoxib. However, in healthy subjects, in small multiple dose studies with 600 mg BID (three times the highest recommended dose) celecoxib had no effect on platelet aggregation and bleeding time compared to placebo.</p><p><strong><u>Clinical efficacy and safety</u></strong></p><p>Several clinical studies have been performed confirming efficacy and safety in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Celecoxib was evaluated for the treatment of the inflammation and pain of osteoarthritis of the knee and hip in approximately 4200 patients in placebo and active controlled trials of up to 12 weeks duration. It was also evaluated for treatment of the inflammation and pain of rheumatoid arthritis in approximately 2100 patients in placebo and active controlled trials of up to 24 weeks duration. Celecoxib at daily doses of 200 mg &ndash; 400 mg provided pain relief within 24 hours of dosing. Celecoxib was evaluated for the symptomatic treatment of ankylosing spondylitis in 896 patients in placebo and active controlled trials of up to 12 weeks duration. Celecoxib at doses of 100 mg BID, 200 mg QD, 200 mg BID and 400 mg QD in these studies demonstrated significant improvement in pain, global disease activity and function in ankylosing spondylitis.</p><p>Five randomised double-blind controlled studies have been conducted including scheduled upper gastrointestinal endoscopy in approximately 4500 patients free from initial ulceration (celecoxib doses from 50 mg &ndash; 400 mg BID). In twelve week endoscopy studies celecoxib (100 &ndash; 800 mg per day) was associated with a significantly lower risk of gastroduodenal ulcers compared with naproxen (1000 mg per day) and ibuprofen (2400 mg per day). The data were inconsistent in comparison with diclofenac (150 mg per day). In two of the 12-week studies the percentage of patients with endoscopic gastroduodenal ulceration was not significantly different between placebo and celecoxib 200 mg BID and 400 mg BID.</p><p>In a prospective long-term safety outcome study (6 to 15 month duration, CLASS study), 5,800 osteoarthritis and 2,200 rheumatoid arthritis patients received celecoxib 400 mg BID (4-fold and 2-fold the recommended osteoarthritis and rheumatoid arthritis doses, respectively), ibuprofen 800 mg TID or diclofenac 75 mg BID (both at therapeutic doses). Twenty-two percent of enrolled patients took concomitant low-dose acetylsalicylic acid (&le;325 mg/day), primarily for CV prophylaxis. For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually. Also for the combined NSAID group there was no statistically significant difference for complicated ulcers (relative risk 0.77, 95 % CI 0.41-1.46, based on entire study duration). For the combined endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the celecoxib group compared to the NSAID group, relative risk 0.66, 95 % CI 0.45-0.97 but not between celecoxib and diclofenac. Those patients on celecoxib and concomitant low-dose acetylsalicylic acid experienced 4-fold higher rates of complicated ulcers as compared to those on celecoxib alone. The incidence of clinically significant decreases in haemoglobin (&gt;2 g/dL), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95 % CI 0.17- 0.48. The significantly lower incidence of this event with celecoxib was maintained with or without acetylsalicylic acid use.</p><p>In a prospective randomised 24 week safety study in patients who were aged &ge;60 years or had a history of gastroduodenal ulcers (users of ASA excluded), the percentages of patients with decreases in haemoglobin (&ge;2 g/dL) and/or haematocrit (&ge;10 %) of defined or presumed GI origin were lower in patients treated with celecoxib 200 mg twice daily (N=2238) compared to patients treated with diclofenac SR 75 mg twice daily plus omeprazole 20 mg once daily (N=2246) (0.2 % vs. 1.1 % for defined GI origin, p = 0.004; 0.4 % vs. 2.4 % for presumed GI origin, p = 0.0001). The rates of clinically manifest GI complications such as perforation, obstruction or haemorrhage were very low with no differences between the treatment groups (4-5 per group).</p><p><strong><u>Cardiovascular safety &ndash; long-term studies involving subjects with sporadic adenomatous polyps</u></strong></p><p>Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e., the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). In the APC trial, there was a dose-related increase in the composite endpoint of CV death, myocardial infarction, or stroke (adjudicated) with celecoxib compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.</p><p>In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of CV death, myocardial infarction, or stroke were 3.4 (95 % CI 1.4 - 8.5) with celecoxib 400 mg twice daily and 2.8 (95 % CI 1.1 - 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0 % (20/671 subjects) and 2.5 % (17/685 subjects) respectively, compared to 0.9 % (6/679 subjects) for placebo. The increases for both celecoxib dose groups versus placebo were mainly due to an increased incidence of myocardial infarction.</p><p>In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint (adjudicated) was 1.2 (95 % CI 0.6 - 2.4) with celecoxib 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3 % (21/933 subjects) and 1.9 % (12/628 subjects), respectively. The incidence of myocardial infarction (adjudicated) was with1.0 % (9/933 subjects) with celecoxib 400 mg once daily and 0.6 % (4/628 subjects) with placebo.</p><p>Data from a third long-term study, ADAPT (The Alzheimer&#39;s Disease Anti-inflammatory Prevention Trial), did not show a significantly increased CV risk with celecoxib 200 mg BID compared to placebo. The relative risk compared to placebo for a similar composite endpoint (CV death, myocardial infarction, stroke) was 1.14 (95 % CI 0.61 - 2.15) with celecoxib 200 mg twice daily. The incidence of myocardial infarction was 1.1 % (8/717 patients) with celecoxib 200 mg twice daily and 1.2 % (13/1070 patients) with placebo.</p><p><strong><u>Prospective Randomised Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen (PRECISION)</u></strong></p><p>The PRECISION study was a double-blind study of cardiovascular safety in OA or RA patients with or at high risk for cardiovascular disease comparing Celecoxib (200-400 mg daily) with Naproxen (750-1000 mg daily) and Ibuprofen (1800-2400 mg daily). The primary endpoint, Antiplatelet Trialists Collaboration (APTC), was an independently adjudicated composite of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction or non-fatal stroke. The study was planned with 80% power to evaluate non-inferiority. All patients were prescribed open-label esomeprazole (20-40 mg) for gastro protection. Patients who were taking low-dose aspirin were permitted to continue therapy, at baseline nearly half of the subjects were on aspirin. Secondary and tertiary endpoints included cardiovascular, gastrointestinal and renal outcomes. The Average Dose dispensed was 209&plusmn;37 mg/day for Celecoxib, 2045&plusmn;246 for Ibuprofen and 852&plusmn;103 for Naproxen<strong>.</strong></p><p>Regarding the primary endpoint, Celecoxib, as compared with either naproxen or ibuprofen, met all four pre-specified non-inferiority requirements, see Table 2.</p><p>Other independently adjudicated secondary and tertiary endpoints included cardiovascular, gastrointestinal and renal outcomes. Additionally, there was a 4-month substudy focusing on the effects of the three drugs on blood pressure as measured by ambulatory monitoring (ABPM).</p><p><strong>Table 2. Primary Analysis of the Adjudicated APTC Composite Endpoint</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:709px"><tbody><tr><td colspan="4"><p><strong>Intent-To-Treat Analysis (ITT, through month 30)</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>Celecoxib 100-200 mg bid</strong></p></td><td><p><strong>Ibuprofen 600-800 mg tid</strong></p></td><td><p><strong>Naproxen 375-500 mg bid</strong></p></td></tr><tr><td><p>N</p></td><td><p>8,072</p></td><td><p>8,040</p></td><td><p>7,969</p></td></tr><tr><td><p>Subjects with Events</p></td><td><p>188 (2.3%)</p></td><td><p>218 (2.7%)</p></td><td><p>201 (2.5%)</p></td></tr><tr><td><p>Pairwise Comparison</p></td><td><p><strong>Celecoxib vs. Naproxen</strong></p></td><td><p><strong>Celecoxib vs. Ibuprofen</strong></p></td><td><p><strong>Ibuprofen vs. Naproxen</strong></p></td></tr><tr><td><p>HR (95% CI)</p></td><td><p>0.93 (0.76, 1.13)</p></td><td><p>0.86 (0.70, 1.04)</p></td><td><p>1.08 (0.89, 1.31)</p></td></tr><tr><td colspan="4"><p><strong>Modified Intent-To-Treat Analysis (mITT, on treatment through month 43)</strong></p></td></tr><tr><td>&nbsp;</td><td><p><strong>Celecoxib 100-200 mg bid</strong></p></td><td><p><strong>Ibuprofen 600-800 mg tid</strong></p></td><td><p><strong>Naproxen 375-500 mg bid</strong></p></td></tr><tr><td><p>N</p></td><td><p>8,030</p></td><td><p>7,990</p></td><td><p>7,933</p></td></tr><tr><td><p>Subjects with Events</p></td><td><p>134 (1.7%)</p></td><td><p>155 (1.9%)</p></td><td><p>144 (1.8%)</p></td></tr><tr><td><p>Pairwise Comparison</p></td><td><p><strong>Celecoxib vs. Naproxen</strong></p></td><td><p><strong>Celecoxib vs. Ibuprofen</strong></p></td><td><p><strong>Ibuprofen vs. Naproxen</strong></p></td></tr><tr><td><p>HR (95% CI)</p></td><td><p>0.90 (0.72, 1.14)</p></td><td><p>0.81 (0.64, 1.02)</p></td><td><p>1.12 (0.889, 1.40)</p></td></tr></tbody></table><p>&nbsp;</p><p>The results were overall numerically similar in the celecoxib and comparator groups for the secondary and tertiary endpoints and there were overall no unexpected safety findings.</p><p>Taken together the PRECISION study indicates that celecoxib at the lowest approved dose of 100 mg twice daily is non-inferior to ibuprofen dosed in the range of 600 mg-800 mg three times daily or naproxen dosed in the range of 375 mg-500 mg twice daily with respect to cardiovascular adverse effects. The cardiovascular risks of the NSAID class, including coxibs, are dose-dependent, therefore, the results for celecoxib 200 mg daily on the composite cardiovascular endpoint cannot be extrapolated to dosing regimens using the higher doses of celecoxib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours. Dosing with food (high fat meal) delays absorption of celecoxib by about 1 hour resulting in a T<sub>max</sub>&nbsp;of about 4 hours and increases bioavailability by about 20%.</p><p>In healthy adult volunteers, the overall systemic exposure (AUC) of celecoxib was equivalent when celecoxib was administered as intact capsule or capsule contents sprinkled on applesauce. There were no significant alterations in C<sub>max</sub>, T<sub>max</sub>&nbsp;or T<sub>1/2</sub>&nbsp;after administration of capsule contents on applesauce.</p><p><strong><u>Distribution</u></strong></p><p>Plasma protein binding is about 97 % at therapeutic plasma concentrations and the medicinal product is not preferentially bound to erythrocytes.</p><p><strong><u>Biotransformation</u></strong></p><p>Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, inactive as COX-1 or COX-2 inhibitors, have been identified in human plasma i.e., a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate.</p><p>Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism.</p><p>In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3, or CYP2C9*3/*3, the median C<sub>max</sub>&nbsp;and AUC<sub>0-24</sub>&nbsp;of celecoxib on day 7 were approximately 4-fold and 7-fold, respectively, in subjects genotyped as CYP2C9*3/*3 compared to other genotypes. In three separate single dose studies, involving a total of 5 subjects genotyped as CYP2C9*3/*3, single-dose AUC<sub>0-24&nbsp;</sub>increased by approximately 3-fold compared to normal metabolisers. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3-1.0 % among different ethnic groups.</p><p>Patients who are known, or suspected to be CYP2C9 poor metabolisers based on previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution (see section 4.2).</p><p>No clinically significant differences were found in PK parameters of celecoxib between elderly African-Americans and Caucasians.</p><p>The plasma concentration of celecoxib is approximately 100 % increased in elderly women (&gt;65 years).</p><p>Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean increase in C<sub>max</sub>&nbsp;of 53 % and in AUC of 26 % of celecoxib. The corresponding values in patients with moderate hepatic impairment were 41 % and 146 % respectively. The metabolic capacity in patients with mild to moderate impairment was best correlated to their albumin values. Treatment should be initiated at half the recommended dose in patients with moderate liver impairment (with serum albumin 25-35 g/l). Patients with severe hepatic impairment (serum albumin &lt;25 g/l) have not been studied and celecoxib is contraindicated in this patient group.</p><p>There is little experience of celecoxib in renal impairment. The pharmacokinetics of celecoxib has not been studied in patients with renal impairment but is unlikely to be markedly changed in these patients. Thus caution is advised when treating patients with renal impairment. Severe renal impairment is contraindicated.</p><p><strong><u>Elimination</u></strong></p><p>Celecoxib is mainly eliminated by metabolism. Less than 1 % of the dose is excreted unchanged in urine. The inter-subject variability in the exposure of celecoxib is about 10-fold. Celecoxib exhibits dose- and time-independent pharmacokinetics in the therapeutic dose range. Elimination half-life is 8-12 hours. Steady state plasma concentrations are reached within 5 days of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical safety data revealed no special hazard for humans based on conventional studies of repeated dose toxicity, mutagenicity or carcinogenicity beyond those addressed in section 4.4, 4.6, and 5.1 of the SmPC.</p><p>Celecoxib at oral doses &ge;150 mg/kg/day (approximately 2-fold human exposure at 200 mg twice daily as measured by AUC<sub>0-24</sub>), caused an increased incidence of ventricular septal defects, a rare event, and foetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were treated throughout organogenesis. A dose-dependent increase in diaphragmatic hernias was observed when rats were given celecoxib at oral doses &ge;30 mg/kg/day (approximately 6-fold human exposure based on the AUC<sub>0-24</sub>&nbsp;at 200 mg twice daily) throughout organogenesis. These effects are expected following inhibition of prostaglandin synthesis. In rats, exposure to celecoxib during early embryonic development resulted in pre-implantation and post-implantation losses, and reduced embryo/foetal survival.</p><p>Celecoxib was excreted in rat milk. In a peri-post natal study in rats, pup toxicity was observed.</p><p>In a 2 year toxicity study an increase in nonadrenal thrombosis was observed in male rat at high doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Composition of Rigorixa 200 mg capsules</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Core Materials</strong></p></td></tr><tr><td><p>LACTOSE MONOHYDRATE</p></td></tr><tr><td><p>SODIUM LAURYL SULPHATE</p></td></tr><tr><td><p>POVIDONE</p></td></tr><tr><td><p>CROSCARMELLOSE SODIUM</p></td></tr><tr><td><p>SODIUM STEARYL FUMARATE</p></td></tr><tr><td><p>HARD GELATIN CAPSULES SIZE-2 WHITE</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years (24 Months)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 <sup>&ordm;</sup>C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rigorixa 200 mg capsules available in pack sizes of 20 capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements, Keep out of the reach &amp; sight of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ALPHA PHARMA, 
Kingdom of SAUDI ARABIA, Rabigh
P.O. Box 23989-6704
Tel: +966 12 21 29013

For any information about this medicinal product, please contact the Regulatory affairs department of authorization holder: 
Saudi Arabia 
Regulatory affairs department 
Riyadh 
Tel: +966112931722 Ex:102 - 104
Email: regulatory@alphapharma.com.sa
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>